- Home
- EML vs GNFT Comparison
EML vs GNFT Comparison
Compare EML & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EML
- GNFT
- Stock Information
- Founded
- EML 1858
- GNFT 1999
- Country
- EML United States
- GNFT France
- Employees
- EML N/A
- GNFT N/A
- Industry
- EML Industrial Machinery/Components
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EML Consumer Discretionary
- GNFT Health Care
- Exchange
- EML Nasdaq
- GNFT Nasdaq
- Market Cap
- EML 191.3M
- GNFT 179.7M
- IPO Year
- EML N/A
- GNFT 2019
- Fundamental
- Price
- EML $26.83
- GNFT $3.74
- Analyst Decision
- EML
- GNFT Strong Buy
- Analyst Count
- EML 0
- GNFT 1
- Target Price
- EML N/A
- GNFT $13.00
- AVG Volume (30 Days)
- EML 10.2K
- GNFT 9.9K
- Earning Date
- EML 03-11-2025
- GNFT 09-19-2024
- Dividend Yield
- EML 1.64%
- GNFT N/A
- EPS Growth
- EML N/A
- GNFT N/A
- EPS
- EML N/A
- GNFT 0.47
- Revenue
- EML $284,461,286.00
- GNFT $86,225,222.00
- Revenue This Year
- EML N/A
- GNFT $145.20
- Revenue Next Year
- EML N/A
- GNFT N/A
- P/E Ratio
- EML $13.24
- GNFT $7.89
- Revenue Growth
- EML 7.70
- GNFT 175.45
- 52 Week Low
- EML $22.63
- GNFT $3.35
- 52 Week High
- EML $35.78
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- EML 40.64
- GNFT 49.41
- Support Level
- EML $27.50
- GNFT $3.68
- Resistance Level
- EML $28.60
- GNFT $4.03
- Average True Range (ATR)
- EML 0.85
- GNFT 0.15
- MACD
- EML -0.06
- GNFT 0.05
- Stochastic Oscillator
- EML 0.00
- GNFT 57.35
About EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.